Publication date: 
9 January 2018
Last updated: 
Publication type: 
Fact Sheet
Intended audience: 
Health professionals

This fact sheet is for health professionals.

Administration of Zostavax to people who are immunocompromised is associated with risk of disseminated disease from the vaccine virus. As a result is is recommended that Zostavax not be administered to patients who are immunocompromised.

This fact sheet provides:

  • contraindication details
  • a guide to safe doses of immunosuppressive therapy for Zostavax administration
  • immunisation contact details
  • links to more information.

These files may not be suitable for users of assistive technology. Request an accessible format.